Plain-English translation of NCT06703606 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called as a replacement for emicizumab, which is a current treatment for severe hemophilia A. Researchers want to learn if is safe and effective when patients switch from emicizumab to this new treatment. Both medications help prevent dangerous bleeding in people whose blood doesn't clot properly on its own.
Some patients on current hemophilia treatments want or need to switch to different options. This study will help doctors understand whether this newer medication works well as an alternative and whether it's safe to make the transition from one treatment to the other.
You likely qualify if…
You likely don't qualify if…
You would stop taking emicizumab and wait at least 2 weeks for it to leave your system. Then you would start receiving injections of the new medication under your skin once per week for 4 months. You would have regular visits with the research team to check blood work, monitor for any side effects, and ensure the medication is working. After the treatment period ends, you would stop the new medication, wait 2 weeks, and then return to your regular bleeding disorder treatment. The entire study lasts about 6 months.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
India